報價延遲最少15分鐘:2025/05/30 12:57 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.305 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.64/-0.75
|
|
企業價值
25.91M
|
| 資產負債 |
|
每股賬面淨值
0.55
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/30 12:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions. |